Information Provided By:
Fly News Breaks for January 24, 2019
BLPH
Jan 24, 2019 | 08:24 EDT
Maxim analyst Caroline Palomeque initiated Bellerophon with a Buy rating and a price target of $3, saying the company's lead product INOpulse is well positioned in the absence of other "FDA-approved treatment options for pulmonary hypertension associated with Interstitial Lung Disease". The analyst notes that shares were down significantly in Q3 of 2018 after the company's phase 3 study in pulmonary arterial hypertension was stopped for futility, but she sees upside from the program's intact clinical path forward and expectations of more data later this year.
News For BLPH From the Last 2 Days
There are no results for your query BLPH